EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Merck's enterprise value is $349,505 Mil.
Merck's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $6,907 Mil. Therefore, Merck's EV-to-EBITDA for today is 50.60.
The historical rank and industry rank for Merck's EV-to-EBITDA or its related term are showing as below:
MRK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.41 Med: 14.11 Max: 52.6
Current: 50.6
During the past 13 years, the highest EV-to-EBITDA of Merck was 52.60. The lowest was 6.41. And the median was 14.11.
MRK's EV-to-EBITDA is ranked worse than 92.08% of 707
companies
in the Drug Manufacturers industry
Industry Median: 13.81
vs MRK: 50.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Merck's stock price is $126.94.
Merck's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.140. Therefore, Merck's PE Ratio for today is 906.71.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Merck EV-to-EBITDA Historical Data
The historical data trend for Merck's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Merck Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
20.77
21.73
12.22
14.03
44.02
Merck Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
14.03
14.54
31.87
23.31
44.02
Competitive Comparison
For the Drug Manufacturers - General subindustry, Merck's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Merck's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Merck's EV-to-EBITDA falls into.
Merck's current Enterprise Value is $349,505 Mil.
Merck's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6,907 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck (NYSE:MRK) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Merck's share price for today is $126.94.
Merck's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Merck's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRK has been successfully added to your 